https://scholars.lib.ntu.edu.tw/handle/123456789/546329
標題: | Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma | 作者: | Kim N. CHIA-HSIEN CHENG Jung I. JA-DER LIANG Shih Y.L. Huang W.-Y. Kimura T. Lee V.H.F. Zeng Z.C. Zhenggan R. Kay C.S. Heo S.J. Won J.Y. Seong J. |
公開日期: | 2020 | 出版社: | Amsterdam:Elsevier B.V. | 卷: | 73 | 期: | 1 | 起(迄)頁: | 121-129 | 來源出版物: | Journal of Hepatology | 摘要: | Background & Aims: Few studies have been conducted to compare the efficacies of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA). Thus, in this multinational study, we compared the effectiveness of SBRT and RFA in patients with unresectable HCC. Methods: The retrospective study cohort included 2,064 patients treated in 7 hospitals: 1,568 and 496 in the RFA and SBRT groups, respectively. More than half of the patients (56.5%) developed recurrent tumors, mainly after transarterial chemoembolization (44.8%). Propensity score matching was performed to adjust for clinical factors (n = 313 in each group). Results: At baseline, the SBRT group had unfavorable clinical features compared to the RFA group, including BCLC stage (B-C 65% vs. 16%), tumor size (median 3.0 cm vs. 1.9 cm), and frequent history of liver-directed treatment (81% vs. 49%, all p <0.001). With a median follow-up of 27.7 months, the 3-year cumulative local recurrence rates in the SBRT and RFA groups were 21.2% and 27.9%, respectively (p <0.001). After adjusting for clinical factors, SBRT was related to a significantly lower risk of local recurrence than RFA in both the entire (hazard ratio [HR] 0.45, p <0.001) and matched (HR 0.36, p <0.001) cohorts. In subgroup analysis, SBRT was associated with superior local control in small tumors (?3 cm) irrespective of location, large tumors located in the subphrenic region, and those that progressed after transarterial chemoembolization. Acute grade ?3 toxicities occurred in 1.6% and 2.6% of the SBRT and RFA patients, respectively (p = 0.268). Conclusions: SBRT could be an effective alternative to RFA for unresectable HCC, particularly for larger tumors (>3 cm) in a subphrenic location and tumors that have progressed after transarterial chemoembolization. Lay summary: It is currently not known what the best treatment option is for patients with unresectable hepatocellular carcinoma. Here, we show that stereotactic body radiation therapy provides better local control than radiofrequency ablation, with comparable toxicities. Stereotactic body radiation therapy appears to be an effective alternative to radiofrequency ablation that should be considered when there is a higher risk of local recurrence or toxicity after radiofrequency ablation. ? 2020 European Association for the Study of the Liver |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083852288&doi=10.1016%2fj.jhep.2020.03.005&partnerID=40&md5=ad38359e9e754fbffc19175ef8d5be48 https://scholars.lib.ntu.edu.tw/handle/123456789/546329 |
ISSN: | 0168-8278 | DOI: | 10.1016/j.jhep.2020.03.005 | SDG/關鍵字: | alpha fetoprotein; decarboxyprothrombin; acute toxicity; adult; aged; art; Article; Asian; cancer patient; cancer radiotherapy; cancer surgery; China; cohort analysis; controlled study; female; Hong Kong; human; human tissue; intermethod comparison; Japan; Korea; liver cell carcinoma; major clinical study; male; multicenter study; premedication; priority journal; radiofrequency ablation; retrospective study; stereotactic body radiation therapy; Taiwan; tissue section; tomotherapy; volumetric modulated arc therapy; adverse event; Asia; cancer grading; cancer staging; chemoembolization; diagnosis; liver cell carcinoma; liver tumor; middle aged; pathology; procedures; prognosis; radiosurgery; risk assessment; risk factor; treatment outcome; tumor recurrence; tumor volume; Asia; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiofrequency Ablation; Radiosurgery; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Tumor Burden |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。